Crinetics appoints Rogério Vivaldi Coelho, M.D., M.B.A. to board of directors
Crinetics Pharmaceuticals, Inc.
Board increased from 6 to 7 members; Vivaldi appointed to Class I director, term expiring at 2022 annual meeting.
Vivaldi also appointed to Audit Committee; receives annual cash retainer of $40,000 plus $7,500 for committee service.
Granted option to purchase 25,000 shares vesting over three years in equal annual installments.
Vivaldi brings over 20 years of rare disease pharma experience, including CEO of Sigilon Therapeutics and prior roles at Bioverativ, Spark, and Genzyme.
the Board approved an increase in its authorized size from six members to seven members and appointed Rogério Vivaldi Coelho, M.D., M.B.A. to fill the vacancy created by such increase and serve as a Class I director
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Rogério Vivaldi Coelho was appointed as Class I Director at Crinetics Pharmaceuticals, Inc..
Action
appointed
Role
Class I Director
Exact text from the filing
the Board approved an increase in its authorized size from six members to seven members and appointed Rogério Vivaldi Coelho, M.D., M.B.A. to fill the vacancy created by such increase and serve as a Class I director
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.